Mei San Tang, MD

Assistant Professor (Clinical), University of Utah School of Medicine

Specialties

• Blood banking/transfusion

Education

• MD—Monash University
• Residency—Clinical Pathology, Washington University in St. Louis
• Fellowship—Blood Banking/Transfusion Medicine, Stanford University

Certification/Affiliations

• American Board of Pathology (Clinical Pathology, Blood Banking/Transfusion Medicine)

Research Interests

•  Optimization or development of testing methodologies
•  Blood safety and emerging infectious diseases

Awards

• Alpha Omega Alpha Honor Medical Society, Washington University in St. Louis

Recent Publications

• Tang MS, Shan H. Current state of gene therapy in sickle cell disease. Vox Sang. 2024;119(6):521-528.
• Tang MS, Shu E, Sussman H, et al. Transfusion outcomes between regular and low yield pathogen reduced platelets across different patient populations in a single institution. Transfusion. 2022;62(10):2012-2019.
• Tang MS, Sempek DS, Rensing KJ, et al. Volume determination methods for hematopoietic progenitor cell products collected by apheresis. Cytotherapy. 2021;23(11):991-995.
• Tang MS, Wang M, Chang SH, et al. Association of Bw4/Bw6 mismatch across class I HLA loci with renal graft outcomes in first time transplants. Hum Immunol. 2021;82(10):767-774.
• Tang MS, Lloyd M, Williams M, et al. Performance evaluation of an automated fentanyl immunoassay. J Appl Lab Med. 2021;6(5):1192-1201.
• Tang MS, Farnsworth CW. Associating SARS-CoV-2 serological assays with protection: where the field stands. Clin Chem. 2021;67(5):707-709.
• Tang MS, Case JB, Franks CE, et al. Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays. Clin Chem. 2020;66(12):1538-1547.
• Tang MS, Hock KG, Logsdon NM, et al. Clinical performance of two SARS-CoV-2 serologic assays. Clin Chem. 2020;66(8):1055-1062.